28 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
Our goal is to maintain and further advance our leadership position within the anti-C5a and anti-C5aR complement space, delivering first-in-class … of clinical development.
Solidify and continue to expand the breadth of our leadership position in the anti-C5a/anti-C5aR space by leveraging the full
424B5
IFRX
InflaRx N.V.
12 Jul 23
Prospectus supplement for primary offering
12:00am
goal is to maintain and further advance our leadership position within the anti-C5a and anti-C5aR complement space, delivering first-in-class autoimmune … induced acute respiratory distress syndrome, or virally induced ARDS.
Solidify and continue to expand the breadth of our leadership position in the anti
F-3
IFRX
InflaRx N.V.
30 Jun 23
Shelf registration (foreign)
4:06pm
about and the development status of our current pipeline of product candidates.
Our Strategy
Our goal is to maintain and further advance our leadership … , or virally induced ARDS.
Solidify and continue to expand the breadth of our leadership position in the anti-C5a/anti-C5aR space by leveraging the full
6-K
EX-99.1
ktvr60n0l2fd
28 Jun 23
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
8:30am
424B5
7c7yljizy
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
sn8cbwrwz2olg
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.3
98fi6obvt
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.2
1s1yk9ck
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
xkcku7q etmo1de
21 May 21
Tony Gibney Joins InflaRx Board of Directors
8:16am
424B5
pa18d yw0j
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
autkd 005hlajmemqlm
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
EX-99.3
7zlm0vj pkq
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.1
bgiacw 0j
17 Sep 20
InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
7:31am
424B5
qp4eje7z 2ug
20 Jul 20
Prospectus supplement for primary offering
9:21am
F-3
qevz1indlnp6g
8 Jul 20
Shelf registration (foreign)
12:00am